Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2009
Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Trial
- Trial
- 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.European radiology · 2014Trial
- Direct Patlak Reconstruction of [International journal of molecular sciences · 2023Article
- The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.Biomedicines · 2022Review
- Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer.Clinical and translational radiation oncology · 2021Article
- Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC).EJNMMI radiopharmacy and chemistry · 2020Article
- Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer.World journal of urology · 2020Article
- Linking cellular metabolism and metabolomics to risk-stratification of prostate cancer clinical aggressiveness and potential therapeutic pathways.Translational andrology and urology · 2018Review
- Accuracy of tumor segmentation from multi-parametric prostate MRI andEJNMMI research · 2018Article
- Metabolic Volumetric Parameters inContrast media & molecular imaging · 2018Article
- Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Molecular imaging and fusion targeted biopsy of the prostate.Clinical and translational imaging · 2017Article
- Targeted 11C-choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy.European journal of hybrid imaging · 2017Article
- Update on advances in molecular PET in urological oncology.Japanese journal of radiology · 2016Review
- Application of Different Imaging Methods in the Early Diagnosis of Primary Hepatic Carcinoma.Gastroenterology research and practice · 2016Review
- Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.Nature reviews. Urology · 2015Review
- PET/MRI in Oncological Imaging: State of the Art.Diagnostics (Basel, Switzerland) · 2015Review
- Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.International journal of radiation oncology, biology, physics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
unlabelledThe aim of the study was to assess whether (11)C-choline PET/CT could identify high-risk primary adenocarcinoma of the prostate.
methods(11)C-choline PET/CT and transpelvic MRI were performed in 14 patients with untreated localized primary adenocarcinoma of the prostate, followed by radical prostatectomy as a form of primary monotherapy within 14 d of in vivo imaging. To allow accurate coregistration of whole-mount histology with in vivo imaging, additional ex vivo MR images of the prostatectomy specimen were obtained. Nonlinear 3-dimensional image deformations were used for registrations of PET/CT, MRI, and histology. Volumes of interest from tumor and benign tissue were defined on the basis of histology and were transferred into coregistered (11)C-choline PET/CT volumes to calculate the mean (T((mean))/B) and maximum (T((max))/B) ratio of tumor to benign prostate background. On the basis of MIB-1/Ki-67 expression in tumor tissues represented on a tissue microarray, we assessed whether (11)C-choline uptake correlated with local Gleason score and tumor proliferation.
resultsHistology confirmed 42 tumor nodules with Gleason scores between 3 + 2 and 4 + 4, with volumes ranging from 0.03 to 12.6 cm(3). T((mean))/B (P < 0.01) and T((max))/B (P < 0.001) ratios were significantly increased in high-Gleason score (>or=4 + 3) lesions versus 3 + 4 and lower disease but failed to distinguish between 3 + 4 disease versus 3 + 3 and lower. T((mean))/B and T((max))/B ratios were significantly increased in tumors with an MIB-1/Ki-67 labeling index greater than or equal to 5% (P < 0.01).
conclusionOn the basis of our preliminary data using ratios of tumor to benign prostate background, (11)C-choline preferentially identified aggressive primary prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.